Healthcare Industry News:  Cardinal Health 

Devices Diagnostics Personnel

 News Release - July 27, 2007

Norman J. Pressman, Ph.D. Announces his Resignation as Executive Chairman, Director, and Chief Scientific Officer of MonoGen, Inc.

CHICAGO, ILLINOIS--(Healthcare Sales & Marketing Network)--Jul 27, 2007 -- Dr. Pressman announced today that by mutual agreement he will resign as the Executive Chairman of the Board and as a MonoGen ("Corporation") (Toronto:MOG.TO ) director immediately, and that he will resign as the Chief Scientific Officer of the Company on July 31, 2007. The Board will appoint a successor to the Chair of the Board in the near future.


Norman Pressman stated "I am pleased to have been able to bring MonoGen to this commercialization stage and wish the Company every possible success going forward. Furthermore, I hope that the early efforts invested by the founding MonoGen team members will grow with the support of the Company's directors, officers and employees to serve well vast numbers of patients and families, healthcare providers, and MonoGen investors." Dr. Pressman also indicated that he intends to remain a significant investor in MonoGen.

Ted S. Geiselman, President and CEO commented "MonoGen is certainly grateful for all of the contributions Norman has made in guiding the company to this point in its evolution. We are confident we can build on this progress to reach our long term goal as a major player in the cytology and pathology diagnostics marketplace."

With operational headquarters in the United States (Greater Chicago area), MonoGen is a medical device company developing an integrated suite of fully automated devices (the SAVANT LABORATORY SYSTEM(TM)) for anatomic and molecular pathology laboratories. The SAVANT LABORATORY SYSTEM(TM) is being designed to automate processes performed by clinical laboratories to reduce their costs, increase throughput, and improve the quality and consistency of results.

The common shares of the Corporation are listed for trading on the Toronto Stock Exchange under the trading symbol "MOG".

Forward-Looking Statements

This press release contains statements that are forward-looking in nature. Statements preceded by the words believe, expect, anticipate, plan, intend, continue, estimate, may, will, and similar expressions are forward-looking statements. Forward-looking statements are based on the Corporation's beliefs and assumptions based on information available at the time the assumption was made. Forward-looking statements relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, new services, market forces, commitments and technological developments, relating to the Corporation. By its nature, such forward-looking information is subject to various risks and uncertainties which could cause the Corporation's actual results and experience to differ materially from the anticipated results or other expectations expressed. Those risks and uncertainties include, but are not limited to MonoGen's ability to raise additional capital, MonoGen's ability to execute its business plan while obtaining and maintaining at all times its various regulatory approvals, the performance of its strategic partners including the performance of Cardinal Health in the commercialization of the Corporation's products in the marketplace and the competitive response from existing and potential competitors. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this document, and the Corporation undertakes no obligation to update publicly or revise any forward looking information, whether as a result of new information, future events or otherwise.


Source: MonoGen, Inc

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.